Touyun Biotech Group Limited released its Monthly Return for the period ended 30 April 2026, confirming that both authorised and issued share capital remained unchanged through the month.

Authorised Capital • The company continues to be authorised to issue up to 12.50 billion ordinary shares at a par value of HKD 0.04, translating into authorised share capital of HKD 500 million.

Issued Shares and Public Float • Issued share count stood at 2,805.95 million ordinary shares with zero treasury shares. • Touyun Biotech confirmed compliance with the Main Board’s public-float requirement of at least 25%.

Share-Option Profile Three option tranches are outstanding, totalling approximately 138.80 million options—about 4.95% of current issued shares: 1) 0.90 million options at an exercise price of HKD 1.34 (granted 25 Apr 2022). 2) 60.20 million options at HKD 0.60 (granted 16 Nov 2020). 3) 77.70 million options at HKD 0.20 (granted 30 Sep 2024), of which 25.87 million shares remain available for future grant under the 2022 scheme.

No New Issues, Redemptions or Treasury Activity • The report records no share issuance, no share repurchase, and no treasury-share movement during April 2026. • The company did not raise funds via option exercises or other convertible instruments in the period.

Compliance Statement The filing is accompanied by the standard board confirmation that all share-related activities comply with Hong Kong listing rules and regulatory requirements.